SCHEMBL2085351

SCHEMBL2085351

OC1CCN(C2CCN(Cc3ccccc3)CC2)CC1

nearest known ligand 0.69

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 1/20 0.61
RAB9A P51151 1/20 0.61
DRD2 P14416 2/20 0.59
DRD4 P21917 2/20 0.59
DRD3 P35462 2/20 0.59
RECQL P46063 1/20 0.59
SMN1; SMN2 Q16637 1/20 0.59
ACHE P22303 2/20 0.56
TSHR P16473 1/20 0.54
CCR3 P51677 1/20 0.54
ALDH1A1 P00352 1/20 0.54
SIGMAR1 Q99720 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL266138 0.90 NPC1 (0.71) NPC1RAB9ADRD2DRD4DRD3
Methane SCHEMBL28444324 0.88 NPC1 (0.69) NPC1RAB9ADRD2DRD4DRD3
Hydrochloric Acid SCHEMBL28652893 0.88 NPC1 (0.69) NPC1RAB9ADRD2DRD4DRD3
SCHEMBL7474570 0.87 TRPV6 (0.58) NPC1RAB9ARECQLSMN1; SMN2ACHE
SCHEMBL22834418 0.87 TRPV6 (0.58) NPC1RAB9ARECQLSMN1; SMN2ACHE
SCHEMBL7899060 0.87 TRPV6 (0.58) NPC1RAB9ARECQLSMN1; SMN2ACHE
SCHEMBL3709310 0.86 RECQL (0.70) DRD2DRD4DRD3RECQLSMN1; SMN2
Ethane SCHEMBL27302230 0.86 ACHE (0.68) NPC1RAB9ADRD2DRD4DRD3
SCHEMBL13990656 0.85 L3MBTL3 (0.68) DRD2DRD4DRD3RECQLSMN1; SMN2
Hydrochloric Acid SCHEMBL3706762 0.85 RECQL (0.68) DRD2DRD4DRD3RECQLSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7897603-B2 Selected CGRP-antagonists, processes for preparing them and their use as pharmaceutical compositions BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2011-03-01 US disclosed
US-20090253680-A1 SELECTED CGRP-ANTAGONISTS, PROCESSES FOR PREPARING THEM AND THEIR USE AS PHARMACEUTICAL COMPOSITIONS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2009-10-08 US disclosed
US-7582625-B2 Selected CGRP antagonists, processes for preparing them and their use as pharmaceutical compositions BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2009-09-01 US disclosed
EP-1770086-A1 Selected CGRP antagonists, process for their preparation as well as their use as medicaments Boehringer Ingelheim Pharma GmbH & Co. KG (DE) 2007-04-04 EP disclosed
US-20070072847-A1 -(4-Hydroxy-3,5-dimethyl-benzyl)-2-[4-(1-methyl-piperidin-4-yl)-piperazin-1-yl]-2-oxo-ethyl 4-(2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl)-piperidine-1-carboxylate; headaches; non-insulin dependent diabetes; antidiabetic agents; cardiovascular/nervous system disorders; antiinflammatory agents BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2007-03-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070072847-A1 -(4-Hydroxy-3,5-dimethyl-benzyl)-2-[4-(1-methyl-piperidin-4-yl)-piperazin-1-yl]-2-oxo-ethyl 4-(2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl)-piperidine-1-carboxylate; headaches; non-insulin dependent diabetes; antidiabetic agents; cardiovascular/nervous system disorders; antiinflammatory agents GPR119, HTR1D, TRPV1 NPC1 1413/4885RAB9A 3982/4885DRD2 441/4885
US-20090253680-A1 SELECTED CGRP-ANTAGONISTS, PROCESSES FOR PREPARING THEM AND THEIR USE AS PHARMACEUTICAL COMPOSITIONS CALCRL, CALCR, BDKRB2 NPC1 1455/4885RAB9A 2050/4885DRD2 240/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.